Home › Trials › NCT06890377
Clinical trial No longer in our active list Observational Ages 35 to 80

Using targeted PET imaging to diagnose Multiple System Atrophy

Official title: Targeted Α-synuclein PET Imaging in the Diagnosis of Multiple System Atrophy

Run by Central South University · NCT06890377 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study is testing a new type of imaging to see if it can help doctors better diagnose and understand the different forms of Multiple System Atrophy in people over 35 who have already been diagnosed.

Quick facts

Study typeObservational
Ages35 Years to 80 Years
SexAll
Enrollment90 (estimated)
SponsorCentral South University
Academic / other
Locations1 site (Hunan, Changsha)
Trial IDNCT06890377 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are individuals over 35 years old with clinically confirmed or probable Multiple System Atrophy.

Probably not a fit

Patients with other neurological disorders or those who cannot undergo neuroimaging will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to utilize targeted α-synuclein PET imaging to explore the pathological load and spatial distribution of α-synuclein in patients diagnosed with Multiple System Atrophy (MSA). The study will assess the effectiveness of this imaging technique as a biomarker for diagnosing different subtypes of MSA, evaluating disease severity and prognosis. Participants will include individuals over 35 years old with clinically confirmed or probable MSA, who have been ruled out for other genetic conditions. The study will not involve any specific interventions or treatments.

Why it matters

Potential benefit: If successful, this study could enhance the accuracy of diagnosing Multiple System Atrophy and improve patient management.

How similar studies have gone: While the approach of using PET imaging for α-synuclein has been explored, this specific application in MSA is relatively novel and not extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Age\> 35 years old, gender is not limited;
* Clinically confirmed MSA and clinically probable MSA according to the 2022 MDS MSA diagnostic criteria;
* all patients had been ruled out of polyQ disease by genetic testing;
* Voluntarily participate in this study and sign the informed consent form.

Exclusion Criteria:

* pregnancy or breastfeeding;
* contraindications to MRI examination or inability to cooperate in completing neuroimaging examination;
* previous history of other neurological disorders or presence of other organic intracranial lesions on neuroimaging that cannot be interpreted by MSA, such as epilepsy, trauma, tumors, or high-grade cerebral white matter degeneration (Fazekas grade 2 and above);
* History of alcohol or drug abuse

Where it's running

  • Third Xiangya Hospital of Central South University
    Hunan, Changsha, China     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Multiple System Atrophy - Cerebellar Subtype (MSA-C) 3Multiple System Atrophy - Parkinsonian Subtype (MSA-P) 4Central South University 18
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.